

The SCGF concentrations of sera from patients with informed consent and who suffer leukemia, pre-leukemia or aleukemic malignant blood diseases were determined by the method of Example 6. Ten healthy individuals, both men and women, who exhibit exhibited normal test levels in the blood cell test were served as control examples, and their serum SCGF concentrations were also determined. The results are shown in Fig. 7.

Please replace the first full paragraph on page 58, beginning with “[i]t was also demonstrated that . . . ,” with the following paragraph.

It was also demonstrated that patients of with leukemia, pre-leukemia or aleukemic malignant blood diseases can be detected at a high sensitivity sensitivity with the use of a cut-off value set down from the values for healthy individuals (Table 4). On the other hand, in spite of being a blood disease as well, no significant difference was observed between the values for patients of with aplastic anemia (AA) and healthy individuals, and this disease was not detectable even with the use of a cut-off value.

Please replace the paragraph on page 59, <sup>fourth</sup> second full paragraph, beginning with “[a]mong KD  
8/22/08 the patients who underwent . . . ,” with the following paragraph.

Among the patients who underwent transplantation of the hematopoietic stem cells, cases with the occurrence of GVHD exhibited significantly higher serum SCGF concentrations in aplastic and recovery phases compared to those in the cases without occurrence of the disease. Thus, the occurrence of GVHD was able to diagnose diagnosed by measuring the serum SCGF concentration.

Please replace the paragraph on page 61, first full paragraph, beginning with “[p]eripheral blood cells of various . . . ,” with the following paragraph.